WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

The Role of Gene Therapy: In the Treatments of Type1 Diabetes Mellitus

Mr. Motipavale Balaji Rameshwar[1]*, Miss.Ragini L.Tandle[2]

[1]B. Pharmacy Final Year Student, Latur College of Pharmacy Hasegaon, SRTMUN
[2]Review Guide, Latur College of Pharmacy Hasegaon, SRTMUN

ABSTRACT:-

Type 1 Diabetes Mellitus (T1DM) results from the autoimmune destruction of insulin-producing β pancreatic cells. In humans, the development of Type 1 Diabetes Mellitus (T1DM) is associated with the inheritance of particular MHC class II alleles that lack a charged amino acid at position 57 of the β-chain. Gene therapy has emerged as one of the potential therapeutic alternatives to treat Diabetes. The main aims of this review is to understand the roles of gene therapy in the treatment and prevention of type 1 diabetes mellitus.

Keywords: Type 1 diabetes mellitus; Gene therapy; β cells; Virus vectors and islet.

INTRODUCTION:-

Diabetes mellitus could be a clinical condition caused by hypoglycaemic agent deficiency or a resistance to hypoglycaemic agent, leading to elevated glucose levels. Type I diabetes (T1DM), could be a chronic sickness caused by reaction destruction of insulin-producing duct gland duct gland cells, leading to progressive and irreversible failure of hypoglycaemic agent production.

Gene medical care is that the technique of delivering or manipulating genetic material within the cell as a therapeutic approach to treat sickness. sequence medical care is meant to inject genetic material into patient cells to make amends for broken genes or to incorporate therapeutic trans-genes. sequence medical care has emerged joined of the present trends in medical specialty for its potential to treat varied diseases like reaction diseases, diabetes, cancers and heart diseases that can't be cured mistreatment standard therapies. The alteration or manipulation of those sequences by gene medical care approach may presumably give a a lot of holistic sickness management or maybe cure T1DM. trendy therapeutic ways obtain to revive the endogenous hypoglycaemic agent production instead of ancient hypoglycaemic agent injection treatment. hypoglycaemic agent sequence medical care refers to the expression of the hypoglycaemic agent sequence during a cell kind that doesn't normally manufacture hypoglycaemic agent, for the aim of restoring euglycemia in diabetic patients. Onset of T1D is mostly at intervals the primary 20 years of life.

History of Gene Therapy:-

The idea of sequence medical care emerged within the 1960's as a consequence of major advancements in biological science and biology that occurred at that point, that set the premise of sequence transfer and genetic science. trendy transfection strategies were combined with polite cell choice systems and DNA technology within the late Seventies.The possibility of successful sequence transfer into class cells for sequence medical care functions was usually recognised with the creation of retroviral vectors within the early Nineteen Eighties.

The transfection of the endocrine sequence into corporal cells was 1st tried in vitro in a very monkey excretory organ cell line that resulted within the expression of proinsulin instead of practical, mature endocrine, thanks to the dearth of professional endocrine converses. Clinical effectualness associate exceedingly|in a very} small-scale trial solidifying an otherwise fatal immunological disorder disorder in kids couldn't be incontestable till the beginning



of the new century. exocrine gland transplantation, 1st performed in 1966, exists within the new millennium as a radical treatment for notably defiant kind I polygenic disease with advanced complications.

Epidemiology:-

Autoimmune diseases are generally women more affected than men. In the majority of the population, however There was no change in the incidence of T1D between the study groups sex. An Australian study of children under 15 years of age reported a higher incidence of T1D in women than in men.Moreover, in the Jamaican population the ratio was 2:3 male to female ratio for T1D.11 However, these findings unlike other populations in which males were more susceptible to develop T1D than women. The ratio of men to women was 3:2 observed in the European population aged 15 to 40 years12 and a similar finding was reported in the Boston study of children under 6 years of age.13 In the United States, T1D accounts for approximately two-thirds of newly diagnosed cases diabetes in individuals under 19 years of age.14 to 17 Peak age for Onset of T1D is between 4 and 6 years, with another peak -circle between 10 and 14 years.18-20 .The incidence of diabetes (both type 1 and type 2) worldwide is 246 million.21 The incidence of T1D in America is 23.per 100,000 people.22 An increased incidence of T1D is recorded worldwide with annual increases in Europe, the Middle East and Australia 2, 5 and 3%.12,23-27 Diagnosis of T1D it has been recorded in more than 13,000 children and adolescents to 19 years per year. The prevalence in America is 2.0 per 1,000 people.The risk of developing T1D increases with distance from the equator increases.29 This observation supports data showing people who develop T1D when they move from areas of low incidence to areas of high incidence. Country with the highest reported incidence of T1D is Finland and Sardinia30 and the lowest incidence is in Asia. Not all similar geographical areas regions show a similar incidence of T1D.This suggests that environmental factors it can also affect the incidence of disease.Viral infections, immunizations, diet, soon exposure to cow's milk, maternal age, history preeclampsia and neonatal jaundice all increase the risk of T1D. on the contrary low birth weight reduces the risk of disease.Different climates are believed to influence occurrence of T1D. However, studies are contradictory and no conclusion can yet be reached whether the climate is changing or not Incidence rate of T1D.

Studies from the United States show that some ethnic groups have a higher incidence compared to others. The highest incidence occurs in Caucasian youth followed by African American and Hispanic youth.The lowest incidence is among Asian/Pacific Islanders and American Indians.

Pathophysiology:-

T1D manifests itself when at least 70-90% is destroyed b-cells producing lin (insulitis) by inflammation motive infiltrate of the differentiation cluster (CD) 8+ and CD4+ T cells, B cells, macrophages; with a predominance of CD8+ T cells (Fig. 1C and D).36-38

Previous studies suggest that complement-mediated lysis and Fas-

Fas-ligand binding triggered apoptosis of inflamed islets.36,39 This

can be compared with Figure 1A and B, which shows normal islets

Langerhans without cellular infiltrate. In the association

autoantibodies are formed with the cellular infiltrate to several pancreatic islet auto-antigens in approximately 85% of individuals with T1D.The main auto antibody detected is against glutamic acid decarboxylase (GAD65). Another auto-anti-bodies include a molecule similar to protein tyrosine phosphatase (IA-2or ICA512) and insulin42, which serve as biomarkers for disease.For example, the presence of anti-GAD65 antibody and a healthy individual or a diabetic is an indication that the individual may require insulin in the future.

Therapy. Randomized trials have been conducted in adults and adolescents conclusively found to be associated with poor glycemic control with long-term vascular consequences. Secondary complications they include nephropathy, retinopathy, neuropathy and cardiovascular disease and were previously reviewed in ref. As such earlier intervention is needed.

Approaches for Gene Therapy in Type 1 of Diabetes:-

Several approaches have long been used to seek a cure for diabetes, including islet transplantation, β cell regeneration, and insulin gene therapy

Insulin Gene Therapy:-

Insulin cistron medical aid is associate approach that may overcome the weakness of islet cell medical aid as a result of its vulnerability to reaction attack. There square measure many obligatory conditions for productive hypoglycaemic agent cistron medical aid. hypoglycaemic agent cistron medical aid refers to the expression of the hypoglycaemic agent cistron during a cell kind that doesn't commonly turn out hypoglycaemic agent, for the aim of restoring euglycemia in diabetic patients. It's presently the foremost promising approach to accomplish a cure for T1DM during a safe, specific and economical manner. However, mimicking a number of the a lot of advanced aspects of hypoglycaemic agent production and secretion in non-β cells has remained a challenge. The molecular structure of functionally active hypoglycaemic agent needs chemical process cleavage of the precursor pre-proinsulin molecule at specific sites. associate economical hypoglycaemic agent cistron medical aid ought to have a good hypoglycaemic agent cistron delivery mechanism, a system of regulation of the hypoglycaemic agent biogenesis that responds to Aldo hexose at intervals extraordinarily slender physiological limits, a system of hypoglycaemic agent process into its active type and a alternative of applicable target cells that possess organic chemistry characteristics kind of like kind of like, however aren't targets for β-cell specific self-reactivity. Cells that specific hypoglycaemic agent and have molecular characteristics that closely agree genuine insulin- secreting cells are made by the foremost effective protocols

Regeneration of β Cells:-

Beta Cell Reactivation is also Viable Treatment for Patients With kind one polygenic disease. Researchers achieved triple-crown reactivation of exocrine gland stem cells to become hypoglycaemic agent expressing, suggesting future potential for exchange destroyed beta cells in patients with kind one polygenic disease with newborn insulin-generating cells. The regeneration of exocrine gland exocrine gland cells that turn out hypoglycaemic agent may be a key therapeutic strategy for polygenic disease. Regeneration of β cells happens through endogenous regeneration or exogenous supplementation, like transplantation of body islets or attachment of latest of latest generated from in vitro cell engineering. Residual supply play a serious role within the style of clinical trials: they will not solely reply to combination therapies that involve metabolic perform stimulants however are the potential supply of latest β-cells**.**

Islet Transplantation:-

Islet cell transplantation involves extracting isle cells from the exocrine gland of a deceased donor and implanting them within the liver of somebody with sort one. the thought of sort one polygenic disorder cells replacement medical aid remained dormant for eighty years till 1972 once Ballinger and Lacy reversed latent diabetes by isle transplantation in rats (Shapiro, 2012). Alpo-transplantation of islets into patients with reaction sort one polygenic disorder could be a re- exposure to automobile matter. The islets are refined, processed, and transferred into another person. Once ingrained, the beta cells in these islets begin to form and unharness internal secretion. isle transplantation in patients with sort one polygenic disorder will cut back or eliminate the internal secretion demand. A undefeated isle cell transplant will considerably improve the standard of life for an individual with polygenic disorder. Once transplanted, the isle cells resume their role of cathartic internal secretion to keep up traditional blood glucose levels in response to food, exercise, and alternative changes within the body. or so seventy % of transplanted sort one diabetic patients achieved internal secretion independence. isle transplantation is presently Associate in Nursing choice for a particular cluster of patients with sort one polygenic disorder solely — those with severe glycemic lability, perennial hypoglycaemia, and unknowingness of hypoglycaemia.

Gene therapy treatment:-

Maintaining euglycemia can be achieved by a series of genetic manipulations; including toler-induction, interference with antigen presentation, interference with co-stimulation of T lymphocytes, use of immuno reg cells, induction of apoptosis, ectopic gene expression, transplantations and immunosuppression. Treatment to normalize blood glucose levels after islet destruction. Ectopic gene expression. Cell type targeted in T1D B-cell and

some gene therapies are being tried again to establish b-cell functions in non-targeted cell immune system. Gene expression in cell types that are not their usual area of expression is called ectopic gene expression Zion. Ectopic gene expression is a widely used technique and bypasses the requirement for immunosuppressive measures because the target for genetic engineering comes from graft recipient and can be an unlimited source of autologous cells. Important properties of b-cells that are essential in blood sugar control involves continuous monitoring glucose levels, regulated transcription and translation of pro- insulin, regulated processing of proinsulin into mature insulin, reg. late storage of mature insulin and regulated secretion of mature insulin insulin to a stimulus such as glucose. Good alternatives to b-cells for manipulation into insulin-producing cells include hepatocytes, fibroblasts, muscle, keratinocytes, neuroendocrine cells and many other endocrine cells. Ectopic expression of insulin has been tested in cells such as mouse pituitary corticotroph (AtT20 cells) in 1983,60 and fibro- blasts in 1987.AtT20 cells are similar to b-cells in that they are able to secrete proinsulin and also express pro- converses ,(PCp)2 and PCp 3, to convert proinsulin into mature insulin.50 However, because AtT20 cells are different of cell type from b-cells of insulin expression in AtT20 cells confirmed that non-b cells can be modified to secrete tench. But to make this finding useful, focus on the genetic cells engineering must have a regulated secretory pathway. Fibroblasts were designed to express proinsulin under metallothionein promoter, but insulin production was constitutive and animals transplanted with modified fibroblasts died of hypoglycemia arising from a lack of regulated insulin release.

CONCLUSION:-

From the review I have come to conclusion that : Over a period of time the gene therapy uses are increased significantly.Secondary complication of diabetes mellitus are reduced by gene therapy and it can be a stronger option for diabetic patients.

REFERENCES:-

[1] S. Mali, Delivery systems for gene therapy, Indian J. Hum. Genet. 19 (1) (2013) 3–8.

[2] K.B. Kaufmann, H. Büning, A. Galy, A. Schambach, M. Grez, Gene therapy on the move, EMBO Mol. Med. 5 (11) (2013) 1642–1661.

[3] G.C. Tsokos, G.T. Nepom, Gene therapy in the treatment of autoimmune diseases, J. Clin. Invest. 106 (2) (2000) 181–183.

[4] X. Liu, S. Zhang, X. Li, P. Zheng, F. Hu, Z. Zhou, Vaccination with a co-expression DNA plasmid containing GAD65 fragment gene and IL-10 gene induces regulatory CD4(+) T cells that prevent experimental autoimmune diabetes, Diabetes Metab. Res. Rev. 32 (6) (2016) 522–533.

[5] S.T. Jerram, R.D. Leslie, The genetic architecture of type 1 diabetes, Genes 8 (8) (2017).

[6] M. Bakay, R. Pandey, H. Hakonarson, Genes involved in type 1 diabetes: an up- date, Genes 4 (3) (2013) 499–521.

[7] Y. Touchefeu, K.J. Harrington, J.P. Galmiche, G. Vassaux, Review article: gene therapy, recent developments and future prospects in gastrointestinal oncology, Aliment. Pharmacol. Ther. 32 (8) (2010) 953–968.

[8] C. Mallol, E. Casana, V. Jimenez, A. Casellas, V. Haurigot, C. Jambrina,

V. Sacristan, M. Morro, J. Agudo, L. Vila, F. Bosch, AAV-mediated pancreatic overexpression of Igf1 counteracts progression to autoimmune diabetes in mice, Mol. Metab. 6 (7) (2017) 664–680.

[9] D.J. Hill, J. Hogg, Expression of insulin-like growth factors (IGFs) and their binding proteins (IGF BPs) during pancreatic development in rat, and modulation of IGF actions on rat islet DNA synthesis by IGF BPs, Adv. Exp. Med. Biol. 321 (1992) 113-20; discussion 121-2..

[10] F. Xia, H. Cao, J. Du, X. Liu, Y. Liu, M. Xiang, Reg3g overexpression promotes beta cell regeneration and induces immune tolerance in nonobese-diabetic mouse model, J. Leukoc. Biol. 99 (6) (2016) 1131–1140.

[11] A. Parikh, A.-F. Stephan, E.S. Tzanakakis, Regenerating proteins and their ex- pression, regulation and signaling, Biomol. Concepts 3 (1) (2012) 57–70.

[12] R. Chen, M.L. Meseck, S.L. Woo, Auto-regulated hepatic insulin gene expression in type 1 diabetic rats, Mol. Ther. 3 (4) (2001) 584–590.

[13] P. Rao, I. Cozar-Castellano, J. Roccisana, R.C. Vasavada, A. Garcia-Ocana, Hepatocyte growth factor gene therapy for islet transplantation, Expert Opin. Biol. Ther. 4 (4) (2004) 507–518.

[14] Y. Lin, Z. Sun, Antiaging gene klotho attenuates pancreatic beta-cell apoptosis in type 1, diabetes, Diabetes 64 (12) (2015) 4298–4311.

[15] S.L. Samson, L. Chan, Gene therapy for diabetes: reinventing the islet, Trends Endocrinol. Metab. 17 (3) (2006) 92–100.

[16] V. Yechoor, V. Liu, A. Paul, J. Lee, E. Buras, K. Ozer, S. Samson, L. Chan, Gene therapy with neurogenin 3 and betacellulin reverses major metabolic problems in insulin-deficient diabetic mice, Endocrinology 150 (11) (2009) 4863–4873.

[17] A. Xie, R. Li, T. Jiang, H. Yan, H. Zhang, Y. Yang, L. Yang, V. Yechoor, L. Chan, W. Chen, Anti-TCRbeta mAb in combination with Neurogenin3 gene therapy re- verses established overt type 1 diabetes in female NOD mice, Endocrinology 158 (10) (2017) 3140–3151.

[18] A.J. Dunbar, C. Goddard, Structure-function and biological role of betacellulin, Int. J. Biochem. Cell Biol. 32 (8) (2000) 805–815.

[19] M.V. Gómez-Gaviro, C.E. Scott, A.K. Sesay, A. Matheu, S. Booth, C. Galichet, R. Lovell-Badge, Betacellulin promotes cell proliferation in the neural stem cell niche and stimulates neurogenesis, Proceedings of the National Academy of Sciences of the United States of America 109 (4) (2012) 1317–1322.

[20] D.M. Nathan, S. Genuth, J. Lachin, P. Cleary, O. Crofford, M. Davis, L. Rand,

C. Siebert, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N. Engl. J. Med. 329 (14) (1993) 977–986.

[21] C.M. McKinnon, K. Docherty, Pancreatic duodenal homeobox-1, PDX-1, a major

regulator of beta cell identity and function, Diabetologia 44 (10) (2001)

1203–1214.

[22] S. Song, K. Goudy, M. Campbell-Thompson, C. Wasserfall, M. Scott-Jorgensen,

J. Wang, Q. Tang, J.M. Crawford, T.M. Ellis, M.A. Atkinson, T.R. Flotte, Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice, Gene Ther. 11 (2) (2004) 181–186.

[23] M.L. Massa, J.J. Gagliardino, F. Francini, Liver glucokinase: an overview on the regulatory mechanisms of its activity, IUBMB Life 63 (1) (2011) 1–6.

[24] M. Bahrebar, M. Soleimani, M.H. Karimi, A. Vahdati, R. Yaghobi, Generation of islet-like cell aggregates from human adipose tissue-derived stem cells by lentiviral overexpression of PDX-1, Int. J. Organ Transplant. Med. 6 (2) (2015) 61–76.

[25] A. Pugliese, Insulitis in the pathogenesis of type 1 diabetes, Pediatr. Diabetes 17 (Suppl 22) (2016) 31–36.

[26] J.W. Yoon, H.S. Jun, Recent advances in insulin gene therapy for type 1 diabetes, Trends Mol. Med. 8 (2) (2002) 62–68.

[27] V. Poitout, C. Rouault, M. Guerre-Millo, G. Reach, Does leptin regulate insulin secretion? Diabetes Metab. 24 (4) (1998) 321–326.

[28] A.T. Cheung, B. Dayanandan, J.T. Lewis, G.S. Korbutt, R.V. Rajotte, M. Bryer-Ash, M.O. Boylan, M.M. Wolfe, T.J. Kieffer, Glucose-dependent insulin release from genetically engineered K cells, Science (New York, N.Y.) 290 (5498) (2000) 1959–1962.

[29] A. Banga, L.V. Greder, J.R. Dutton, J.M. Slack, Stable insulin-secreting ducts formed by reprogramming of cells in the liver using a three-gene cocktail and a PPAR agonist, Gene Ther. 21 (1) (2014) 19–27.

[30] D. Li, B. Zhao, Y. Luo, S. Limbara, B. Zhao, X. Zou, W. Yang, Y. Li, Transplantation of Aire-overexpressing bone marrow-derived dendritic cells delays the onset of type 1 diabetes, Int. Immunopharmacol. 49 (2017) 13–20.

[31] A. Finckh, C. Gabay, At the horizon of innovative therapy in rheumatology: new biologic agents, Curr. Opin. Rheumatol. 20 (3) (2008) 269–275.

[32] J. Chan, W. Clements, J. Field, Z. Nasa, P. Lock, F. Yap, B.H. Toh, F. Alderuccio, Transplantation of bone marrow genetically engineered to express proinsulin II protects against autoimmune insulitis in NOD mice, J. Gene Med. 8 (11) (2006) 1281–1290.

[33] N. Michel, W. Osen, L. Gissmann, T.N. Schumacher, H. Zentgraf, M. Muller, Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination, Virology 294 (1) (2002) 47–59.

[34] G.J. Prud'homme, Prevention of autoimmune diabetes by DNA vaccination, Expert Rev. Vaccines 2 (4) (2003) 533–540.

[35] M.C. Johnson, B. Wang, R. Tisch, Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes, Hum. Vaccin. 7 (1) (2011) 27–36.

[36] C. Meagher, G. Arreaza, A. Peters, C.A. Strathdee, P.A. Gilbert, Q.S. Mi,

P. Santamaria, G.A. Dekaban, T.L. Delovitch, CCL4 protects from type 1 diabetes by altering islet beta-cell-targeted inflammatory responses, Diabetes 56 (3) (2007) 809–817.

[37] T. Shigihara, A. Shimada, Y. Oikawa, H. Yoneyama, Y. Kanazawa, Y. Okubo,

K. Matsushima, E. Yamato, J. Miyazaki, A. Kasuga, T. Saruta, S. Narumi, CXCL10 DNA vaccination prevents spontaneous diabetes through enhanced beta cell pro- liferation in NOD mice, J. Immunol. (Baltim. Md.: 1950) 175 (12) (2005) 8401–8408.

[38] X. Wang, A. Zhang, Y. Liu, S. Chen, Z. Feng, W. Shang, M. Maziarz, J. Radtke, C.S. Hampe, Anti-idiotypic antibody specific to GAD65 autoantibody prevents type 1 diabetes in the NOD mouse, PLoS One 7 (2) (2012) e32515.

[39] P.P. Pagni, D. Bresson, T. Rodriguez-Calvo, A. Bel Hani, Y. Manenkova,

N. Amirian, A. Blaszczak, S. Faton, S. Sachithanantham, M.G. von Herrath, Combination therapy with an anti-IL-1beta antibody and GAD65 DNA vaccine can reverse recent-onset diabetes in the RIP-GP mouse model, Diabetes 63 (6) (2014) 2015–2025.

[40] L. Chatenoud, Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?, Nature reviews, Endocrinology 6 (3) (2010) 149–157.

[41] T. Orban, K. Farkas, H. Jalahej, J. Kis, A. Treszl, B. Falk, H. Reijonen, J. Wolfsdorf,

A. Ricker, J.B. Matthews, N. Tchao, P. Sayre, P. Bianchine, Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B- chain immunotherapy, J. Autoimmun. 34 (4) (2010) 408–415.

[42] A.W. Michels, G.S. Eisenbarth, Immune intervention in type 1 diabetes, Semin. Immunol. 23 (3) (2011) 214–219.

[43] A.Y. Savinov, P. Burn, Interference with islet-specific homing of autoreactive T cells: an emerging therapeutic strategy for type 1 diabetes, Drug Discov. Today 15 (2010) 13–14 531-9.

[44] B.K. Sack, R.W. Herzog, C. Terhorst, D.M. Markusic, Development of gene transfer for induction of antigen-specific tolerance, Mol. Therapy Methods Clin. Dev. 1 (2014) 14013.

[45] M.A. Coleman, C.F. Jessup, J.A. Bridge, N.H. Overgaard, D. Penko, S. Walters, D.J. Borg, R. Galea, J.M. Forbes, R. Thomas, P.T. Coates, S.T. Grey, J.W. Wells, R.J. Steptoe, Antigen-encoding bone marrow terminates islet-directed memory CD8+ T-cell responses to alleviate islet transplant rejection, Diabetes (2016).

[46] W. Chen, A. Xie, L. Chan, Mechanistic basis of immunotherapies for type 1 dia- betes mellitus, Transl. Res. 161 (4) (2013) 217–229.

[47] C.M. Hull, L.E. Nickolay, M. Estorninho, M.W. Richardson, J.L. Riley, M. Peakman, J. Maher, T.I. Tree, Generation of human islet-specific regulatory T cells by TCR gene transfer, J. Autoimmun. 79 (2017) 63–73.

[48] N. Giannoukakis, M. Trucco, Gene therapy for type 1 diabetes, Am. J. Ther. 12 (6) (2005) 512–528.

[49] W.I. Yeh, H.R. Seay, B. Newby, A.L. Posgai, F.B. Moniz, A. Michels, C.E. Mathews, J.A. Bluestone, T.M. Brusko, Avidity and bystander suppressive capacity of human regulatory t cells expressing de novo autoreactive T-Cell receptors in type 1 dia- betes, Front. Immunol. 8 (2017) 1313.

50. Cheung AT, Dayanandan B, Lewis JT, Korbutt GS, Rajotte RV, et al. (2000) Glucose-dependent insulin release from genetically engineered K cells. Science 290: 1959-1962.

51. Yamane S, Harada N, Inagaki N (2016) Mechanisms of fat-induced gastric inhibitory polypeptide/glucose-dependent insulinotropic polypeptide secretion from K cells. J Diabetes Investig 1: 20-26.

52. Dong H, Woo SL (2001) Hepatic insulin production for type 1 diabetes. Trends Endocrinol Metab 12: 441-446.

53. Hughes SD, Quaade C, Johnson JH, Ferber S, Newgard CB (1993) Transfection of AtT-20ins cells with GLUT-2 but not GLUT-1 confers glucose-stimulated insulin secretion. Relationship to glucose metabolism. J Biol Chem 268: 15205-15212.

54. Mas A, Montané J, Anguela XM, Muñoz S, Douar AM, et al. (2006) Reversal of type 1 diabetes by engineering a glucose sensor in skeletal muscle. Diabetes 55: 1546-1553.

55. Jaén ML, Vilà L, Elias I, Jimenez V, Rodó J, et al. (2017) Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs. Mol Ther Methods Clin Dev 6: 1-7.

56. He CX, Shi D, Wu WJ, Ding YF, Feng DM, et al. (2004) Insulin expression in livers of diabetic mice mediated by hydrodynamics- based administration. World J. Gastroenterol 10: 567-572.

57. Niu L, Xu YC, Xie HY, Dai Z, Tang HQ (2008) Expression of human insulin gene wrapped with chitosan nanoparticles in NIH3T3 cells and diabetic rats. Acta Pharmacol Sin 29: 1342-1349.

58. Niu L, Xu YC, Dai Z, Tang HQ (2008) Gene therapy for Type 1 diabetes mellitus in rats by gastrointestinal administration of chitosan nanoparticles containing human insulin gene. World J Gastroenterol 14: 4209-4215.

59. Rasouli M, Allaudin ZN, Omar AR, Ahmad Z (2013) Insulin secreted from genetically engineered intestinal cells reduces blood glucose levels in diabetic mice. Curr Gene Ther 13: 229-239.

60. Sato M, Inada E, Saitoh I, Ohtsuka M, Nakamura S, et al. (2013) Site- targeted non-viral gene delivery by direct DNA injection into the pancreatic parenchyma and subsequent in vivo electroporation in mice. Biotechnol J 8: 1355-1361.

61. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, et al. (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672.

62. Kolodka TM, Finegold M, Moss L, Woo SL (1995) Gene therapy for diabetes mellitus in rats by hepatic expression of insulin. Proc Natl Acad Sci USA 92: 3293-3297.

63. Muzzin P, Eisensmith RC, Copeland KC, Woo SL (1997) Hepatic insulin gene expression as treatment for type 1 diabetes mellitus in rats. Mol Endocrinol 11: 833-837.

64. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, et al. (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72: 9873-9880.

65. Ren B, O'Brien BA, Swan MA, Koina ME, Nassif N, et al. (2007) Long- term correction of diabetes in rats after lentiviral hepatic insulin gene therapy. Diabetologia 50: 1910-1920.

Journal of Diabetes Research and Therapy Open Access Journal

66. Ren B, O'Brien BA, Byrne MR, Ch'ng E, Gatt PN, et al. (2013) Long- term reversal of diabetes in non-obese diabetic mice by liver- directed gene therapy. J Gene Med 15: 28-41.

67. Gerace D, Ren B, Hawthorne WJ, Byrne MR, Phillips PM, et al. (2013) Pancreatic transdifferentiation in porcine liver following lentiviral delivery of human furin-cleavable insulin. Transplant Proc 45: 1869- 1874.

68. Volpers C, Kochanek S (2004) Adenoviral vectors for gene transfer and therapy. J Gene Med 6: S164-S171.

69. Wold WS, Doronin K, Toth K, Kuppuswamy M, Lichtenstein DL, et al. (1999) Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. Curr Opin Immunol 11: 380-386.

70. McCaffrey AP, Fawcett P, Nakai H, McCaffrey RL, Ehrhardt A, et al. (2008) The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol Ther 16: 931-941.

71. Alba R, Bosch A, Chillon M (2005) Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 12: S18-S27.

72. Short DK, Okada S, Yamauchi K, Pessin JE (1998) Adenovirus- mediated transfer of a modified human proinsulin gene reverses hyperglycemia in diabetic mice. Am J Physiol 275: E748-E756.

73. Atchison RW, Casto BC, Hammon WM (1965) Adenovirus-associated defective virus particles. Science 149: 754-756.

74. McCarty DM, Young SM Jr, Samulski RJ (2004) Integration of adeno- associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 38: 819-845.

75. Deyle DR, Russell DW (2009) Adeno-associated virus vector integration. Curr Opin Mol Ther 11: 442-447.

76. Sugiyama A, Hattori S, Tanaka S, Isoda F, Kleopoulos S, et al. (1997) Defective adenoassociated viral-mediated transfection of insulin gene by direct injection into liver parenchyma decreases blood glucose of diabetic mice. Horm Metab Res 29: 599-603.

77. Park YM, Woo S, Lee GT, Ko JY, Lee Y, et al. (2005) Safety and efficacy of adeno-associated viral vector-mediated insulin gene transfer via portal vein to the livers of streptozotocin-induced diabetic Sprague- Dawley rats. J Gene Med 7: 621-629.

78. Gan SU, Notaridou M, Fu ZY, Lee KO, Sia KC, et al. (2016) Correction of Murine Diabetic Hyperglycaemia With A Single Systemic Administration of An AAV2/8 Vector Containing A Novel Codon Optimized Human Insulin Gene. Curr Gene Ther 16: 65-72.

79. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, et al. (2010) Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 21: 704-712.

80. Nathwani AC, Tuddenham EGD, Rangarajan S, Rosales C, McIntosh J, et al. (2011) Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365.

81. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, et al. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347.

82. Image source- Google.com